

**Remarks**

The instant Office Action has required restriction to one of the following inventions under 35 U.S.C. §121:


Group I: Claims 1-71, drawn to methods and compositions for treating cancer employing several different types of heterocyclic compounds, classified in class: unstated, subclass: unstated.

Group II: Claims 72-91, drawn to methods for treating cancer employing an enhanced combination of the group I compounds and a hyperplastic inhibitory agent, classified in class: unstated, subclass: unstated (hyperplastic inhibitory is classified in class 514).

Applicants respectfully elect Group I without traverse. In particular, Applicants hereby elect the Group I invention (claims 1-71) drawn to methods and compositions for treating cancer employing several different types of heterocyclic compounds for prosecution in this application with traverse.

Further, in order to reduce the burden for searching the Group I invention, for the purposes of searching, Applicants elect to search the core structure wherein X= C.

If a telephone conversation with Applicants' Agent would expedite the prosecution of the above-identified application, the examiner is urged to call Applicants' Agent at (617) 227-7400.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP  
  
Cynthia L. Kanik, Ph.D.  
Registration No. 37,320  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: September 26, 2003